Folate Deficiency: Neural Tube Defects, Anaemia, and Fortification Policy in Africa

In Sub-Saharan Africa, the estimated prevalence of neural tube defects (NTDs) ranges from 1 to 10 per 1,000 live births across different regions - figures that are broadly two to five times higher than those observed in countries where mandatory folic acid fortification of staple foods has been in place for over two decades.¹ In the United States, mandatory fortification of wheat flour introduced in 1998 was followed by a 26–36% reduction in NTD-affected pregnancies; in Canada, the corresponding decline exceeded 40%.² The contrast is sharp. Across most of SSA, fortification programmes either do not exist, are voluntary rather than mandatory, or achieve coverage too partial to generate population-level reductions in NTD prevalence. The result is a largely preventable burden of spina bifida, anencephaly, and encephalocele that falls disproportionately on women with the least access to periconceptional supplementation.

Folate - a collective term encompassing both naturally occurring food folates and synthetic folic acid - occupies a central position in maternal and child nutrition because the critical developmental window for NTD prevention is narrow and occurs before most women know they are pregnant. Neural tube closure is complete by approximately 28 days post-conception. By the time a pregnancy is confirmed and a clinician recommends supplementation, that window has typically closed. This biological fact drives the entire policy logic of periconceptional supplementation and population-level fortification: because individual behaviour change cannot reliably deliver adequate folate status at the moment it matters most, the burden of prevention must shift to food supply.

Folate Biochemistry and Physiological Functions

Folate functions biochemically as a one-carbon carrier, donating and accepting single-carbon units in pathways central to nucleotide synthesis and amino acid metabolism. Its role in thymidylate synthesis makes folate availability rate-limiting for DNA replication; cells dividing rapidly - early embryonic tissues, erythrocyte precursors in the bone marrow - are disproportionately affected when supply is inadequate. The methylation cycle, through which folate cooperates with vitamin B12 to regenerate methionine from homocysteine, links folate status to a wide range of downstream methylation reactions affecting gene expression, neurotransmitter synthesis, and vascular function.

Natural food folates are chemically diverse - polyglutamate forms that must be enzymatically cleaved in the intestinal brush border before absorption - and their bioavailability from whole foods is approximately 50% relative to the synthetic monoglutamate form, folic acid. This disparity underpins the dietary folate equivalent (DFE) unit used in dietary reference intake calculations: 1 µg of food folate equals 1 DFE, while 1 µg of synthetic folic acid taken with food equals 1.7 DFE, and folic acid taken on an empty stomach equals 2 DFE. Recommended intakes for women of reproductive age sit at 400 µg DFE per day, rising to 600 µg DFE during pregnancy.

The genetic polymorphism MTHFR 677C>T reduces the efficiency of the enzyme that converts dietary folate to its active methylated form (5-methyltetrahydrofolate). Homozygous TT individuals have enzyme activity approximately 70% lower than the CC genotype and are at elevated risk of NTDs, megaloblastic anaemia, and hyperhomocysteinaemia under conditions of borderline folate intake. The TT genotype frequency in African populations is lower than in European or Hispanic populations - typically 1–4% versus 10–15% - but this relative protection is erased by dietary folate intakes that are inadequate across the full population.

Deficiency Symptoms and Clinical Manifestations

Megaloblastic Anaemia

The haematological consequence of folate deficiency is megaloblastic anaemia - a morphologically distinct anaemia characterised by large, immature red cell precursors (megaloblasts) in the bone marrow and hypersegmented neutrophils in peripheral blood. Impaired DNA synthesis disrupts nuclear maturation while cytoplasmic development proceeds normally, producing cells whose nuclei are abnormally large relative to the cytoplasm. The resulting erythrocytes are macrocytic (mean corpuscular volume typically >100 fL), fragile, and short-lived.

The clinical presentation is often insidious. Fatigue, pallor, glossitis, and angular cheilitis may precede the development of frank anaemia by weeks. Folate deficiency anaemia in pregnancy is clinically significant not only for maternal wellbeing but because it reduces oxygen delivery to the developing foetus and is associated with low birthweight and preterm delivery.³ Stevens and colleagues, analysing data from 107 countries, estimated that anaemia in pregnancy affected 38% of pregnant women globally, with the highest burdens in SSA and South Asia; the contribution of folate deficiency to this burden is substantial, though it overlaps considerably with iron deficiency, which is the dominant nutritional cause of anaemia in most populations.⁴

Distinguishing folate-deficiency megaloblastic anaemia from that caused by vitamin B12 deficiency is clinically important: the haematological presentations are virtually identical, but vitamin B12 deficiency carries neurological consequences (subacute combined degeneration) that folate supplementation does not prevent and may, at high doses, partially mask. Measurement of serum folate, red cell folate, serum vitamin B12, and plasma homocysteine together with methylmalonic acid allows differentiation in most cases.

Neural Tube Defects

The mechanism linking folate inadequacy to NTDs involves its role in the rapid cell division and differentiation required for neural tube closure. Precisely how suboptimal folate impairs neural tube closure remains incompletely characterised - leading hypotheses centre on impaired nucleotide biosynthesis, altered methylation of developmental genes, and increased cellular apoptosis - but the epidemiological and interventional evidence that folic acid supplementation reduces NTD risk is among the most robust in nutritional epidemiology.

Spina bifida, in which the posterior neural tube fails to close, is the most common survivable NTD. Its severity ranges from spina bifida occulta (clinically silent) to myelomeningocele, in which the spinal cord and meninges protrude through the vertebral defect, causing lower limb paralysis, bladder and bowel dysfunction, and often hydrocephalus. Anencephaly, resulting from failure of the anterior neural tube to close, is incompatible with prolonged survival. Encephalocele, in which brain tissue herniates through a skull defect, carries intermediate prognosis depending on the extent of neural involvement.

Elevated Homocysteine

Folate deficiency impairs the methylation cycle by reducing the availability of 5-methyltetrahydrofolate, the methyl donor required to convert homocysteine to methionine. The resulting hyperhomocysteinaemia - plasma homocysteine above approximately 15 µmol/L - is associated with endothelial dysfunction, arterial stiffness, and elevated cardiovascular risk. In pregnancy, hyperhomocysteinaemia is associated with placental vascular dysfunction, abruption, and pre-eclampsia. Whether homocysteine lowering through folate supplementation translates into cardiovascular event reduction remains contested in clinical trial evidence, but its role as a marker of folate inadequacy is well-established.

Periconceptional Supplementation: The Trial Evidence

The key evidence for folic acid in NTD prevention derives from two large randomised trials conducted in the early 1990s. The MRC Vitamin Study Research Group, reporting in the Lancet in 1991, demonstrated that periconceptional supplementation with 4 mg folic acid per day reduced the recurrence risk of NTDs in women who had already had an affected pregnancy by 72%.¹ This was a recurrence-prevention trial - participants were all women with a prior NTD-affected pregnancy and hence at substantially elevated baseline risk - but the magnitude of the effect was striking.

Czeizel and Dudas, publishing in the New England Journal of Medicine in 1992, reported on a randomised controlled trial among Hungarian women with no prior NTD history, demonstrating that 0.8 mg folic acid per day in a multivitamin formulation reduced the first occurrence of NTDs by approximately 83% compared with a trace-element supplement control.⁵ Together, these trials established beyond reasonable doubt that folic acid periconceptional supplementation prevents both first occurrence and recurrence of NTDs. They also established that the effective dose for first-occurrence prevention is far lower than the 4 mg used in the MRC trial, with 0.4–0.8 mg widely adopted in national recommendations for women of reproductive age.

Subsequent meta-analyses, including that of Bhutta and colleagues in The Lancet’s 2013 nutrition series, confirmed the consistency of the periconceptional folic acid effect and estimated the contribution of supplementation programmes to child survival and health.⁶ The challenge - and it is not a small one - is that supplementation relies on women knowing they may become pregnant, having access to supplements, and taking them consistently before and in the earliest weeks of pregnancy. In SSA, where a substantial proportion of pregnancies are unplanned and the first antenatal visit may occur in the second trimester, supplementation strategies can reach only a fraction of the at-risk population.

Iron-Folic Acid Versus Folic Acid Alone in Pregnancy

Antenatal care guidelines across SSA routinely provide iron-folic acid (IFA) supplementation rather than folic acid alone, reflecting the co-occurrence of iron deficiency and folate deficiency in most pregnant women and the substantial overlap between the two in producing anaemia. The standard WHO recommendation of 60 mg elemental iron and 400 µg folic acid daily during pregnancy addresses both deficiencies simultaneously.

Whether the iron component of IFA adversely affects folate absorption has been investigated, with reassuring findings: there is no clinically meaningful interaction at standard supplementation doses. The programmatic argument for IFA over folic acid alone is strong - the marginal cost of adding iron is minimal, iron deficiency anaemia is the predominant nutritional contributor to maternal anaemia in SSA, and combining the two micronutrients simplifies supply chain and adherence logistics. Multiple micronutrient supplements (MMS) containing 15 micronutrients including iron and folic acid have been evaluated in SSA contexts and show modest benefits over IFA for birth outcomes in some trials, though debates about cost-effectiveness, supply chain complexity, and programmatic implementation persist.³

The limitation of all antenatal supplementation approaches is timing: they begin after neural tube closure. For NTD prevention specifically, the relevant intervention window lies before most women present to antenatal services.

Folic Acid Fortification: Global Evidence and SSA Coverage

Population-level fortification of staple foods with folic acid addresses the timing problem that periconceptional supplementation cannot. By raising the folate status of all women consuming fortified foods - including those who are pregnant without knowing it - fortification provides a background level of protection that does not depend on individual health-seeking behaviour.

The strongest evidence for the effectiveness of mandatory fortification comes from North America. Botto and colleagues, analysing data across 58 countries, demonstrated that in countries with mandatory wheat flour fortification, NTD prevalence was considerably lower than in those with no fortification programme, with an estimated 13,000 NTD-affected births prevented annually in fortifying countries.⁷ Sayed and colleagues documented the South African experience directly: after South Africa introduced mandatory fortification of maize meal and wheat flour with folic acid in 2003, NTD prevalence at a tertiary hospital in Johannesburg declined by 41% over the subsequent four years - one of the few direct pre–post evaluations available from SSA.⁸ De Wals and colleagues reported the Canadian experience, showing a 46% reduction in NTD prevalence in the province of Quebec following mandatory fortification, with comparable findings across Canadian provinces.²

Coverage of mandatory folic acid fortification in SSA remains limited. As of 2023, the Food Fortification Initiative database listed South Africa, Nigeria, and a small number of other SSA countries as having mandatory large-scale wheat flour fortification regulations that include folic acid, but enforcement capacity, milling infrastructure fragmentation, and the dominance of home-milled or locally-ground grains in rural populations substantially reduce effective coverage. In much of rural SSA, the staple food is not produced through industrial milling - it is maize, cassava, or sorghum processed at household or community level, which lies entirely outside the food fortification system. This structural feature means that the SSA populations with the lowest baseline folate intakes and least access to supplementation are also least likely to benefit from flour fortification.

Dietary Folate Sources and the SSA Context

Green leafy vegetables - kale, spinach, amaranth, cowpea leaves - are among the richest dietary sources of food folate and are, in principle, accessible in many parts of SSA. Legumes, particularly black-eyed peas and groundnuts, also provide meaningful folate. The dietary diversity problem in SSA is therefore not primarily about the absence of folate-containing foods but about dietary patterns dominated by staple starch with limited consumption of dark green vegetables and legumes. Seasonal availability, post-harvest losses, and the substantial cooking-related destruction of folate (estimated at 50–80% loss with prolonged boiling) further reduce effective intake.

Black and colleagues estimated that global dietary folate intake was inadequate in a high proportion of women in SSA, with dietary surveys in Ethiopia, Nigeria, and Mozambique consistently recording mean intakes below 250 µg DFE per day - well below the 400 µg DFE recommendation for non-pregnant women of reproductive age, and far below the 600 µg recommended during pregnancy.³

Limitations

This review draws primarily on data from studies in South Africa, Nigeria, and Ethiopia, which may not generalise to all SSA contexts given the heterogeneity of dietary patterns, health system infrastructure, and NTD surveillance capacity across the region. NTD prevalence data in SSA are underestimates: many affected pregnancies are not captured in hospital-based surveillance, stillbirths and early infant deaths occur outside health facilities, and anencephalic births may not be recorded. The evidence base for folic acid fortification effectiveness within SSA rests heavily on the South African experience; generalisability to countries with different staple food systems, enforcement capacity, and baseline folate status is uncertain. Most randomised trial evidence for periconceptional supplementation originates from European and Asian populations; while the biochemical mechanism is universal, the interaction with co-existing micronutrient deficiencies in SSA populations merits continued investigation.

Frequently Asked Questions

What is the difference between folate and folic acid? Folate is the generic term for the vitamin B9 family found naturally in foods, primarily as polyglutamate forms with a bioavailability of roughly 50% relative to synthetic folic acid. Folic acid is the stable, fully oxidised synthetic form used in supplements and fortification, which has higher bioavailability. The dietary folate equivalent (DFE) system accounts for this difference: 1 µg food folate equals 1 DFE, while 1 µg synthetic folic acid taken with food equals 1.7 DFE.

How does folate deficiency cause neural tube defects? Neural tube closure occurs at approximately 22–28 days post-conception and requires rapid cell division and differentiation. Folate is essential for nucleotide synthesis and DNA replication during this process. When folate status is inadequate, the precise mechanism of neural tube closure failure likely involves impaired cellular proliferation and possibly altered methylation of developmental genes, though the full mechanistic picture remains under investigation. The key clinical implication is that supplementation must begin before conception, as the critical window closes before most pregnancies are recognised.

Why does fortification have a greater population impact than supplementation alone? Periconceptional supplementation requires women to anticipate pregnancy, access supplements, and take them consistently during the weeks before and after conception. Because a large proportion of pregnancies are unplanned and first antenatal visits in SSA often occur in the second trimester, supplementation programmes cannot reliably reach all women during the critical NTD prevention window. Fortification of staple foods raises population-level folate status continuously, without requiring individual health-seeking behaviour, covering women whose pregnancies are unplanned or unrecognised.

What explains the higher NTD rates in SSA compared with North America or Europe? The higher NTD burden in SSA reflects a combination of lower baseline dietary folate intakes (dietary patterns with limited green vegetable and legume consumption), lower coverage of periconceptional supplementation programmes, and the near-absence of effective mandatory folic acid fortification of widely consumed staple foods. North American and European countries have had mandatory fortification in place since the late 1990s and benefit from broader antenatal care coverage with earlier gestational age at first visit. SSA’s structural barriers - including reliance on home-milled grains that cannot be fortified through industrial means - make direct transfer of fortification strategies challenging.

Related reading: Maternal Nutrition and Pregnancy Outcomes | Iron Deficiency, Anaemia, and the Global Burden